Contribute Try STAT+ Today

A combination pill from Myovant Sciences met its primary goal of reducing pain from endometriosis, the biotech company said Tuesday, the second late-stage trial to show the drug’s effectiveness in women with the condition.

Myovant (MYOV), a biotech based in Switzerland with U.S. operations in Brisbane, Calif., has also been testing the hormone blocker, called relugolix, as a treatment for uterine fibroids and advanced prostate cancer. On Monday, the company received a priority review of relugolix for advanced prostate cancer from the Food and Drug Administration, meaning the agency will expedite its decision on whether to approve the drug for these patients. A study comparing standard injected therapy to the oral relugolix, published in the New England Journal of Medicine on June 4, showed better outcomes for men who took relugolix.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.